Recursion Pharmaceuticals, Inc. (RXRX) Free cash flow 2019–2025
Recursion Pharmaceuticals, Inc. (RXRX) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$378.3MFY2025 · since FY2019: -$61.0M → -$378.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$378.3M | -1.5% |
| FY2024 | -$372.9M | -24.4% |
| FY2023 | -$299.7M | -148.6% |
| FY2022 | -$120.6M | +39.2% |
| FY2021 | -$198.4M | -287.3% |
| FY2020 | -$51.2M | +16.0% |
| FY2019 | -$61.0M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More RXRX financial trends
RXRX RevenueRXRX Net incomeRXRX Net marginRXRX Gross profitRXRX Gross marginRXRX Operating incomeRXRX Operating marginRXRX Operating cash flowRXRX Capital expendituresRXRX Return on equityRXRX Stock buybacksRXRX Dividends paidRXRX Total assetsRXRX Total liabilitiesRXRX Shareholders’ equityRXRX overview →